Some examples include bedside and FDA-approved B-type natriuretic peptide (BNP) immunosensor POC platforms (e.g., Abbott AxSYM® BNP, Alere Triage® BNP, and i-STAT BNP) for use on suspected ischemic stroke patients [74,76]; TBI Check® for combinatorial analysis of biomarkers H-FABP, and GFAP for use in brain injury or mild traumatic brain injury (mTBI) detection; the POCs based on fluid phase enzymatic activities or semi-solid phase bioluminescence for plasma NSE monitoring [77]; the lateral flow POC technology detection of c-Fn [78,79]. This evidence concerns the gene NPPB and ischemic stroke.